版本:
中国

Shire's treatment for primary immunodeficiency wins FDA approval

Sept 14 Shire Plc said the United States Food and Drug Administration (FDA) approved its treatment for patients with primary immunodeficiency, a group of genetic disorders in which part of the body's immune system is missing or functions improperly.

The drug, Cuvitru, is already approved in 17 European countries, and the company expects to launch it in the United States in the coming weeks, Shire said on Wednesday. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta)

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐